Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IOVA
stocks logo

IOVA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
82.29M
+11.66%
-0.167
-35.77%
82.76M
+67.79%
-0.155
-57.04%
97.56M
+62.73%
-0.148
-55.2%
Estimates Revision
The market is revising Downward the revenue expectations for Iovance Biotherapeutics, Inc. (IOVA) for FY2025, with the revenue forecasts being adjusted by -4.16% over the past three months. During the same period, the stock price has changed by -11.65%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.08%
In Past 3 Month
Stock Price
Go Down
down Image
-11.65%
In Past 3 Month
Wall Street analysts forecast IOVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOVA is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast IOVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOVA is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.200
sliders
Low
4.00
Averages
6.50
High
9.00
Current: 2.200
sliders
Low
4.00
Averages
6.50
High
9.00
Barclays
Overweight
maintain
$4 -> $9
2025-11-24
Reason
Barclays
Price Target
$4 -> $9
2025-11-24
maintain
Overweight
Reason
Barclays raised the firm's price target on Iovance Biotherapeutics to $9 from $4 and keeps an Overweight rating on the shares. The firm expects meaningful indication expansion and margin improvements to drive longer-term upside in the shares.
Goldman Sachs
NULL -> Sell
downgrade
$1
2025-11-10
Reason
Goldman Sachs
Price Target
$1
2025-11-10
downgrade
NULL -> Sell
Reason
Goldman Sachs raised the firm's price target on Iovance Biotherapeutics to $1.50 from $1 and keeps a Sell rating on the shares.
H.C. Wainwright
Buy
downgrade
$20 -> $9
2025-10-29
Reason
H.C. Wainwright
Price Target
$20 -> $9
2025-10-29
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Iovance Biotherapeutics to $9 from $20 and keeps a Buy rating on the shares ahead of the Q3 report on November 6. The firm believes Iovance "is squarely in the investor's penalty box." It remains positive on the shares but believes the company is in a "show-me" stage.
Wells Fargo
Overweight
maintain
$18 -> $14
2025-08-08
Reason
Wells Fargo
Price Target
$18 -> $14
2025-08-08
maintain
Overweight
Reason
Wells Fargo lowered the firm's price target on Iovance Biotherapeutics to $14 from $18 and keeps an Overweight rating on the shares. While the stock reacted negatively after-hours to Q2 results, the firm notes the revenue miss was mainly due to IL-2, with AMTAGVI meeting consensus. Wells sees clear path to delivering 2025 guidance with modest IL-2 growth and AMTAGVI trajectory in Q3 and Q4.
Goldman Sachs
Neutral -> Sell
downgrade
$8 -> $1
2025-07-15
Reason
Goldman Sachs
Price Target
$8 -> $1
2025-07-15
downgrade
Neutral -> Sell
Reason
Goldman Sachs downgraded Iovance Biotherapeutics to Sell from Neutral with a price target of $1, down from $8. The firm cites the slower than expected launch of the company's lead drug Amtagvi in second-line melanoma for the downgrade. Key opinion leader discussions and a physician survey indicate underutilization of Amtagvi due to a limited eligible patient population as well as logistical and operational complexities, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$20
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20
2025-07-14
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating on Iovance Biotherapeutics with a $20 price target after the company announced real-world, retrospective data from patients treated with commercial Amtagvi. The drug demonstrated "impressive" clinical responses, particularly in earlier stage patients, the analyst tells investors in a research note. The firm points out that among 41 evaluable patients treated at four authorized treatment centers, the physician-assessed objective response rate was 48.8%. It believes Amtagvi is working as intended, and even exceeding expectations in less heavily treated patients, post commercialization.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Iovance Biotherapeutics Inc (IOVA.O) is -3.64, compared to its 5-year average forward P/E of -7.14. For a more detailed relative valuation and DCF analysis to assess Iovance Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.14
Current PE
-3.64
Overvalued PE
-2.34
Undervalued PE
-11.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.68
Undervalued EV/EBITDA
-10.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
42.88
Current PS
0.00
Overvalued PS
171.00
Undervalued PS
-85.24
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 296.59% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

IOVA News & Events

Events Timeline

(ET)
2025-11-13
08:45:02
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-11-06 (ET)
2025-11-06
08:08:52
Iovance Biotherapeutics announces Q3 earnings per share of 25 cents, below consensus estimate of 26 cents.
select
2025-11-03 (ET)
2025-11-03
07:20:55
Iovance Biotherapeutics Shares Clinical Findings from Phase 2 IOV-LUN-202 Study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Iovance (IOVA) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
3.5
11-24Newsfilter
Oncotelic Raises GMP Bio Valuation to $1.7 Billion
  • Asset Valuation Increase: Oncotelic Therapeutics announced that its 45% stake in GMP Bio is now valued at approximately $765 million, reflecting the company's leadership in oncology treatment. This valuation increase is closely tied to GMP Bio's scientific advancements, marking Oncotelic's transition from scientific validation to financial recognition.
  • Accelerated Clinical Progress: Oncotelic's pipeline includes multiple candidates advancing in clinical stages, such as OT-101 for pancreatic cancer and OXi4503 for acute myeloid leukemia. These advancements not only enhance the company's competitive position but also lay the groundwork for future commercialization.
  • Nanomedicine Platform Development: Oncotelic's Deciparticle nanomedicine platform is progressing toward commercialization, with clinical studies for Sapu-003 set to begin soon. The success of this platform will further elevate the company's market value and attract investor interest.
  • Strong Intellectual Property Foundation: Oncotelic holds over 75 issued patents and more than 500 applications, establishing a robust intellectual property base. This foundation supports future collaboration and licensing opportunities, particularly amid growing investment interest in the biopharma sector.
[object Object]
Preview
3.5
11-24Globenewswire
Biotech Valuations Increase as Innovative Clinical Platforms Demonstrate Advancement

  • Oncotelic Therapeutics' Valuation Update: Oncotelic Therapeutics is preparing for a significant fair-value update on its 45% stake in GMP Bio, with an independent assessment suggesting a valuation increase to approximately $1.7 billion, translating to an implied asset value of around $765 million for Oncotelic.

  • Clinical Progress and Pipeline Development: The company has made notable advancements in its clinical programs, including multiple candidates in late-stage development targeting oncology and rare diseases, which strengthens its position in the biotech sector.

  • Importance of Fair-Value Reporting: Fair-value reporting under U.S. GAAP is becoming crucial for development-stage biopharma companies, allowing for a clearer understanding of the financial implications of scientific advancements and aligning them with enterprise value.

  • Nanomedicine Commercialization Potential: Oncotelic's Deciparticle nanomedicine platform is progressing towards commercialization, with promising developments in drug delivery systems that could significantly enhance therapeutic efficacy and market value as the global nanomedicine market expands.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Iovance Biotherapeutics Inc (IOVA) stock price today?

The current price of IOVA is 2.2 USD — it has decreased -0.45 % in the last trading day.

arrow icon

What is Iovance Biotherapeutics Inc (IOVA)'s business?

Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.

arrow icon

What is the price predicton of IOVA Stock?

Wall Street analysts forecast IOVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOVA is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Iovance Biotherapeutics Inc (IOVA)'s revenue for the last quarter?

Iovance Biotherapeutics Inc revenue for the last quarter amounts to 67.46M USD, increased 15.20 % YoY.

arrow icon

What is Iovance Biotherapeutics Inc (IOVA)'s earnings per share (EPS) for the last quarter?

Iovance Biotherapeutics Inc. EPS for the last quarter amounts to -0.25 USD, decreased -10.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Iovance Biotherapeutics Inc (IOVA)'s fundamentals?

The market is revising Downward the revenue expectations for Iovance Biotherapeutics, Inc. (IOVA) for FY2025, with the revenue forecasts being adjusted by -4.16% over the past three months. During the same period, the stock price has changed by -11.65%.
arrow icon

How many employees does Iovance Biotherapeutics Inc (IOVA). have?

Iovance Biotherapeutics Inc (IOVA) has 838 emplpoyees as of December 05 2025.

arrow icon

What is Iovance Biotherapeutics Inc (IOVA) market cap?

Today IOVA has the market capitalization of 873.33M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free